Abstract Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in vivo are complex and may involve modulation of autonomic outflow in both the central and peripheral nervous systems as well as direct effects on the myocardium and vasculature. Although several lines of evidence indicate that the cardiovascular depressive effects of cannabinoids are mediated by peripherally localized CB 1 receptors, recent studies provide strong support for the existence of as-yet-undefined endothelial and cardiac receptor(s) that mediate certain endocannabinoid-induced cardiovascular effects. The endogenous cannabinoid system has been recently implicated in the mechanism of hypotension associated with hemorrhagic, endotoxic, and cardiogenic shock, and advanced liver cirrhosis. Furthermore, cannabinoids have been con-
Introduction
The biological effects of marijuana and its main psychoactive ingredient, ∆ 9 -tetrahydrocannabinol (THC), are mediated by specific, G protein-coupled receptors (GPCRs) (Howlett et al. 1990 ). To date, two cannabinoid (CB) receptors have been identified by molecular cloning: the CB 1 receptor, which is by far the most abundant of all neurotransmitter receptors in the brain (Matsuda et al. 1990 ), but is also present in various peripheral tissues including the heart and vasculature (Gebremedhin et al. 1999; Liu et al. 2000; Bonz et al. 2003) , and the CB 2 receptor, expressed primarily by immune (Munro et al. 1993 ) and hematopoietic cells (Valk and Delwel 1998) . The natural ligands of these receptors are endogenous, lipid-like substances called endocannabinoids, which include arachidonoyl ethanolamide or anandamide and 2-arachidonoylglycerol (2-AG), as the two most widely studied members of this group (reviewed by Mechoulam et al. 1998 ).
Cannabinoids and their synthetic and endogenous analogs are best known for their prominent psychoactive properties, but their cardiovascular effects were also recognized as early as the 1960s. The most important component of these effects is a profound decrease in arterial blood pressure, cardiac contractility, and heart rate (Lake et al. 1997a,b; Hillard 2000; Kunos et al. 2000 Kunos et al. , 2002 Randall et al. 2002; Ralevic et al. 2002; Hiley and Ford 2004) . Although several lines of evidence indicate that the cardiovascular depressive effects of cannabinoids are mediated by peripherally localized CB 1 receptors, cannabinoids can also elicit vascular and cardiac effects, which are independent of CB 1 and CB 2 receptors, as discussed in detail later in this chapter.
Recent findings implicate the endogenous cannabinoid system in the pathomechanism of hypotension associated with various forms of shock, including hemorrhagic (Wagner et al. 1997 ), endotoxic (Varga et al. 1998 Wang et al. 2001; Liu et al. 2003; Bátkai et al. 2004a) , and cardiogenic shock (Wagner et al. 2001a (Wagner et al. , 2003 , as well as the hypotension associated with advanced liver cirrhosis (Bátkai et al. 2001; Ros et al. 2002) . Furthermore, the possible use of cannabinoids as novel antihypertensive agents has been entertained (Birmingham 1973; Archer 1974; Varma et al. 1975; Crawford and Merritt 1979; Zaugg and Kynel 1983; Lake et al. 1997b; Bátkai et al. 2003 and 2004; Li et al. 2003) . In addition, a protective role of endocannabinoids has been described in myocardial ischemia (reviewed in Hiley and Ford 2003, 2004) .
